Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
Status:
Withdrawn
Trial end date:
2020-11-24
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to establish a safe and tolerable dose combination (the
"maximum tolerated dose") of selinexor and ixazomib when used together for the treatment of
patients with certain types of advanced sarcoma. The study will enroll patients with advanced
dedifferentiated liposarcoma, malignant peripheral nerve sheath tumor, alveolar soft part
sarcoma and Ewing sarcoma. Future studies to further evaluate the safety and anti-cancer
efficacy of this treatment for sarcoma will use the dose combination determined in this
study.